MDL | - |
---|---|
Molecular Weight | 451.30 |
Molecular Formula | C20H20Cl2N4O4 |
SMILES | O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)/C(C[N+]([O-])=O)=N/O |
JKE-1674 is an orally active glutathione peroxidase 4 ( GPX4 ) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors [1] [2] [3] .
GPX4 [1]
JKE-1674 exhibits activity indistinguishable from that of ML210 in cellular target engagement assays including yielding the same +434Da GPX4 adduct in cells. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML210 and is completely rescued by ferroptosis inhibitors. JKE-1674 forms a nitrile-oxide electrophile in cells. JKE-1674 dehydration yields a nitrile-oxide electrophile that binds GPX4. JKE-1674 exhibits far greater stability than chloroacetamide inhibitors [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
JKE-1674 (50 mg/kg; p.o.) can be detected in the serum of mice dosed orally with the compound [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | SCID mice [1] |
Dosage: | 50 mg/kg (Pharmacokinetic Analysis) |
Administration: | P.o. |
Result: | Could be detected in the serum of mice dosed orally with the compound. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 100 mg/mL ( 221.58 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2158 mL | 11.0791 mL | 22.1582 mL |
5 mM | 0.4432 mL | 2.2158 mL | 4.4316 mL |
10 mM | 0.2216 mL | 1.1079 mL | 2.2158 mL |